2019
Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition
Miccio JA, Verma V, Kelly J, Kann BH, An Y, Park HS, Eskander A, Burtness B, Husain Z. Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition. Oral Oncology 2019, 99: 104447. PMID: 31630059, DOI: 10.1016/j.oraloncology.2019.104447.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell carcinomaExtranodal extensionLymphovascular invasionKaplan-Meier overall survival analysisContralateral lymph node involvementHPV-positive oropharyngeal cancerFuture staging systemsNational Cancer DatabaseLymph node involvementLymph nodal involvementSquamous cell carcinomaAJCC eighth editionOverall survival analysisPathologic nodalInferior OSNodal involvementNode involvementWorse OSClinical stagingPrognostic factorsOropharyngeal cancerPositive marginsPrognostic importanceCell carcinomaCox regressionOA01 Impact of Contralateral Lymph Node Involvement on Survival of Surgically-Managed HPV-Positive Oropharyngeal Cancer Staged with the AJCC Eighth Edition
Miccio J, Kelly J, Kann B, An Y, Park H, Verma V, Mehra S, Judson B, Burtness B, Husain Z. OA01 Impact of Contralateral Lymph Node Involvement on Survival of Surgically-Managed HPV-Positive Oropharyngeal Cancer Staged with the AJCC Eighth Edition. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e1. DOI: 10.1016/s0360-3016(19)30402-x.Peer-Reviewed Original Research
2014
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
Burtness B, Bourhis JP, Vermorken JB, Harrington KJ, Cohen E. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Trials 2014, 15: 469. PMID: 25432788, PMCID: PMC4289298, DOI: 10.1186/1745-6215-15-469.Peer-Reviewed Original ResearchMeSH KeywordsAfatinibAntineoplastic AgentsCarcinoma, Squamous CellChemoradiotherapyChemotherapy, AdjuvantClinical ProtocolsDisease-Free SurvivalDouble-Blind MethodErbB ReceptorsHead and Neck NeoplasmsHumansMolecular Targeted TherapyNeoplasm Recurrence, LocalNeoplasm StagingProtein Kinase InhibitorsQuality of LifeQuinazolinesResearch DesignRisk FactorsSquamous Cell Carcinoma of Head and NeckTime FactorsTreatment OutcomeConceptsEpidermal growth factor receptorDisease-free survivalErbB family membersAdvanced diseaseOropharynx cancerOverall survivalEndpoint measuresUnfavourable riskPrimary siteHigh-risk HNSCC patientsHPV-positive oropharynx cancerIrreversible ErbB family blockerDisease-free survival ratesRandomized phase II trialNeck squamous cell carcinomaErbB family blockerHigh-risk headHigh-risk HNSCCPrimary endpoint measureGood clinical conditionEvidence of diseaseLymph node involvementPhase II trialPhase III studyUnacceptable adverse events